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Background: Several tests are performed to obtain better accuracy when diagnosing Amer-
ican tegumentary leishmaniasis (ATL). It is believed that antigens released via secretion,
excretion and metabolism are more speciﬁc than are antigens released by the lysis of Leish-
mania parasites. Such antigens are known as exo-antigens (exo-Ag) and are formed from
products released by cultured parasites in a way that is similar to that in which they cause
infections in hosts.
Objective: We attempted to validate a Leishmania mexicana ELISA exo-Ag for ATL diagnosis in
Midwestern Brazil.
Methods: A total of 281 patients were included in the study. We  analysed pre-treatment blood
from  98 ATL patients; out of those, 85.7% and 14.3% had cutaneous and mucosal forms,
respectively.Results: The exo-Ag accuracy was 83.99% (95% CI = 79.24–87.81) with a sensitivity
% CI = 83.46–95.09) and an overall speciﬁcity value of 80.33% (95%value  of 90.82% (95CI  = 73.97–85.44). The positive predictive value and negative predictive value were 71.20%
(95%  CI = 62.72–78.41) and 94.23% (95% CI = 89.40–96.94), respectively. Among healthy con-
trols, exo-Ag had a speciﬁcity of 91.25% (95% CI = 83.02–95.70); additionally, the test had
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speciﬁcity rates of 66.67% (95% CI = 46.71–82.03) in Chagas disease patients, 60.61% (95%
CI  = 43.68–75.32) in patients with rheumatic diseases, 76.92% (95% CI = 49.74–91.82) in pem-
phigus foliaceus patients, 87.50% (95% CI = 52.91–97.76) in leprosy patients, 87.50% (95%
CI  = 63.98–96.50) in VRDL-positive patients, and 77.78 (95% CI = 45.26–93.68) in deep mycosis
patients.
Conclusion: Based on the indicators of validity, we conclude that the results obtained in this
study enable the recommendation of the exo-Ag ELISA for ATL diagnosis once it presented
a  reasonable accuracy compared to classical methods. Cost evaluations are necessary to
completely deﬁne the role of this technique in large scale.
© 2015 Elsevier Editora Ltda. All rights reserved.
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introduction
merican tegumentary leishmaniasis (ATL) is an infectious
nd difﬁcult-to-control disease that is caused by parasites
f the genus Leishmania. ATL causes considerable socioeco-
omic losses, as it affects subjects at their most productive
ges.1
Several complimentary tests are used to diagnose ATL, all
f which have limitations. The diagnostic tests include par-
site detection techniques (e.g., direct examination, cultures,
istopathological examinations and PCR) and immunodiag-
ostic techniques (e.g., cellular immune response detection,
ncluding the Montenegro skin test (MST), antibody detec-
ion, including the ﬂuorescent antibody test (IFAT), ELISA, and
mmunocomplex antigen detection).2,3 Serological tests have
een given considerable importance in epidemiological inves-
igations. However, for diagnostic purposes, those methods
an be associated with a relatively high proportion of false-
ositive results.
ELISAs have a great advantage among other serological
ests because of their higher speciﬁcity. In addition to quickly
enerated results, ELISAs are also relatively low-cost tests.4,5
he antigens most commonly used in leishmaniasis diag-
ostic immunoenzymatic assays are obtained from intact
arasites. The sensitivities of these assays ﬂuctuate between
5% and 100% for crude antigens.6 Crude antigens from
eishmania (Leishmania) amazonensis and Leishmania (Viannia)
raziliensis, when separated by electrophoresis and subjected
o Western blotting, can be recognized by sera from patients
ith Chagas disease.7 This phenomenon is believed to occur
ecause of interactions with Trypanosoma and Leishmania com-
on antigens.8
On the other hand, it is believed that antigens released via
ecretion, excretion and metabolism are more  speciﬁc than
re antigens released by the lysis of Leishmania parasites.9,10
uch antigens are known as exo-antigens (exo-Ag) and are
ormed from products released by cultured parasites in a way
hat is similar to that in which they cause infections in hosts.11
n ELISA with Leishmania (Leishmania) mexicana (L. mexicana)
romastigote antigens, used to detect IgM and IgG antibodies
n sera from Brazilian Leishmania-infected patients, had a sen-
itivity of 92.3% and was reactive when tested in 10 patients
ith ATL via Western blotting.12
ELISA with an exo-Ag from Leishmania parasites cultured
n protein-free medium is thought to be an improved methodwith increased accuracy; therefore, we intended to validate
this technique for ATL diagnosis in Midwestern Brazil.
Materials  and  methods
This study was conducted from August 2007 to July 2010 at the
Hospital Universitário de Brasília, Brasília, Brazil, a reference
centre for ATL in Midwestern Brazil. Ninety-eight consecu-
tive patients with cutaneous (CL) and mucocutaneous (MCL)
disease forms, who were speciﬁc treatment naive during the
previous six months, were included in a cross-sectional study
for diagnostic test accuracy.
ATL diagnosis was performed according to a previously val-
idated composite reference standard formed by clinical and
laboratory criteria (direct examination, culture, histopatholog-
ical examination, PCR from lesion fragments, MST  and IFAT).13
Leishmania subgenus identiﬁcation was performed at the Labo-
ratory of Dermatology, Hospital das Clínicas, University of São
Paulo, Ribeirão Preto, Brazil, using restriction fragment length
polymorphism (RFLP) as described elsewhere.13
Additionally, the study included a convenience sample
of 80 healthy patients with no epidemiological history of
leishmaniasis, 24 patients with Chagas disease, 13 patients
with American pemphigus foliaceus, 8 patients with leproma-
tous leprosy, 9 patients with deep mycosis, 16 VRDL-positive
patients at a minimum dilution of 1:8, and 33 patients
with rheumatic disease who were positive for at least one
rheumatic marker test, including anti-streptolysin O (ASO),
C-reactive protein (CRP), and rheumatoid factor (RF).
Sampling
Two millilitres of patient serum, obtained through venipunc-
ture, was used. After clot retraction, the samples were
centrifuged and stored in labelled tubes at −20◦ C until the
ELISA exo-Ag analyses were performed.
L.  mexicana  exo-antigen  ELISA
A manufactured kit was used for the ELISA reactions. The
kit, developed by the Cellabs laboratory (Brookvale, Aus-
tralia), contained the following components: one ELISA plate
with 12 detachable strips, each of which contained eight
wells pre-coated with Leishmania exo-antigens; one vial of
washing buffer (PBS-Tween, 20× concentrate); one vial of
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Fig. 1 – Exo-Ag ELISA results for the control subgroups
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peroxidase-conjugated anti-human IgG (100× concentrate);
one vial of substrate (20× concentrate); one vial of substrate
buffer; one vial of stop solution; one vial of positive control
serum; and one vial of negative control serum.
The patients’ sera and the positive and negative controls
were diluted 1:200 in the washing solution and pipetted into
an ELISA plate that had been pre-coated with L. mexicana
secretory, excretory, and metabolic antigens. The plate was
subsequently incubated for 60 min  in a humid chamber. After
washing the plate four times with PBS plus Tween 20 (0.05%),
the peroxidase-conjugated anti-human IgG (diluted 1:100 in
washing solution) was added to the plate. Next, the plate was
incubated again for 30 min  at room temperature, and the plate
was washed four more  times with PBS-Tween. One millilitre
of chromogenic substrate (TMB) pre-diluted in substrate buffer
was added to the wells, and the plate was immediately covered
with aluminium foil. After a 30-min incubation at room tem-
perature, 100 L of stop solution (H2SO4) was added to each
well. The reactions were observed with an ELISA reader (Spec-
tramax Plus, Molecular Devices LLC, Sunnyvale, CA, USA) that
was ﬁtted with a 450/620-nm absorbance ﬁlter.
Samples with absorbance values above the cut-off point
(0.3%; above the grey zone) were considered positive. The
ELISA reactions were performed and results were evaluated by
a specialized biomedicist who was blind to the real condition
of patients included.
Sample  size
The sample size was calculated based on the hypothesis test
for a proportion, available in Epi Info version 3.3.2 (CDC, Geor-
gia, USA) software. According to the sensitivity of ELISA tests
for ATL in previously published studies,12,14 considering a con-
ﬁdence level of 95% and an absolute precision of 5%, the
number of patients to be included for serological tests was
deﬁned as 73 patients and 73 controls.
Statistical  analysis
The test properties (sensitivity and speciﬁcity values, the pos-
itive predicted value, and the negative predicted value, and
accuracy) were evaluated using OpenEpi® version 3.01 (Emory
University, Rollins School of Public Health, Atlanta, Georgia,
USA). Conﬁdence intervals were set at 95% (95% CI).
This study was approved by the Ethics in Research Com-
mittee of the College of Medicine – University of Brasília – UnB
(Process number 046/2007). All patients included signed the
informed consent form and the study was in accordance to
the Declaration of Helsinki, as revised in 2013.
Results
Epidemiological  and  clinical  aspects
Ninety-eight ATL patients were included, of whom 67.4% were
men  and 32.6% were women; 70.4% patients had only one skin
lesion, while 22.4% had two-four lesions and only three (3.1%)
had ﬁve or more  skin lesions. Regarding the clinical disease
forms, 85.7% had CL, while 14.3% had MCL. Additionally, 81.6%of the patients had initial infections, while 12.2% had recurrent
disease, and no information was available for six patients.
When assessing the sensitivity of the composite reference
standard tests, MST was the most sensitive (88.5%), followed
by PCR (75.9%) and IFAT (73.1%) (Table 1). RFLP-PCR was per-
formed for samples obtained from 58 patients (Table 1). The
subgenera Viannia was identiﬁed in 95.5% of the 44 positive
samples, and the subgenera Leishmania was identiﬁed in two
patients (4.5%).
L.  mexicana  exo-antigen  ELISA
The exo-Ag ELISA overall accuracy was 83.99% (95%
CI = 79.24–87.81) with a sensitivity value of 90.82% (95%
CI = 83.46–95.09) and an overall speciﬁcity value of 80.33% (95%
CI = 73.97–85.44). The positive predictive value and the nega-
tive predictive value were 71.20% (95% CI = 62.72–78.41) and
94.23% (95% CI = 89.40–96.94), respectively.
The exo-Ag ELISA speciﬁcity varied according to the group
studied: healthy patients, patients with other diseases, and
also in VDRL-positive sera (Table 2). Fig. 1 shows the exo-Ag
ELISA reaction results for the groups of patients with other
diseases and in VDRL-positive sera (minimum cut-off value,
0.3) (Fig. 1). The exo-Ag ELISA showed false positive results in
13 of the 33 patients with rheumatic diseases (Table 3).
Discussion
Parasite detection methods are recommended as a way to
achieve an accurate diagnosis. Given the low sensitivity of
these tests, immunological techniques such as ELISA, IFAT,
and MST  have also been employed. The exo-Ag ELISA test has
been studied as a potentially better option for ATL diagnosis.
Direct examination sensitivity ranges from 14 to 89.7%,
depending on the parasite species and the disease evolution
period.13 Parasite cultures from ATL patients also yield low
and variable positivity rates (28.6–89%).13,15,16 Additionally, the
limitations of this technique, including bacterial and fungal
contamination and delays to provide the ﬁnal result (up to 30
days), should be taken into account.
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Table 1 – Sensitivity of assays used to diagnose samples from 98 patients with American cutaneous leishmaniasis who
were treated at the University Hospital of Brasília from August 2007 to July 2010.
Result Culture DE IFAT MST PCR HE Exo-Ag ELISA
Positive 47 45 68 62 44 19 89
Negative 43 46 24 8 14 73 9
NP 8 7 6 28 40 6 0
Sensitivity (52.2) (49.5) (73.9) (88.5) (75.9) (20.7) (90.8)
NP, exam not performed; DE, direct examination; IFAT, immunoﬂuorescence antibody test; MST, Montenegro skin test; *HE, histopathological
examination with the presence of amastigote forms.
Table 2 – Leishmania mexicana exo-Ag ELISA speciﬁcity according to the group of control subjects evaluated.
Group Samples (n) False positive (n) Speciﬁcity: (95% CI)a
Healthy subjects 80 7 91.25 (83.02–95.70)
Chagas disease 24 8 66.67 (46.71–82.03)
Pemphigus foliaceus 13 3 76.92 (49.74–91.82)
Leprosy 8 1 87.50 (52.91–97.76)
Deep mycosis 9 2 77.78 (45.26–93.68)
VRDL-positive patients 16 2 87.50 (63.98–96.50)
Rheumatic diseases 33 13 60.61 (43.68–75.32)
Total 183 36 80.33 (73.97–85.44)
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da 95% CI, 95% conﬁdence interval.
PCR is considered as the most accurate method for ATL.3
owever, a variable sensitivity is expected depending on the
peciﬁc technique used. Our results are aligned with previ-
us data and conﬁrm that Leishmania (Viannia) braziliensis is
he most frequent species in the region studied.16–19 Similar
o other techniques for immunologic tests in leishmaniasis,
uch as the MST,13 the decision of using L. mexicana antigens
or the ELISA tests is based on the fact that parasites of the
eishmania subgenus are more  easily managed in laboratory
xperiments and grow faster in culture media. This action can
ave an important impact on cost reduction when considering
ts reproduction on larger scale.
The exo-Ag ELISA performed well by exhibiting a higher
ensitivity than did the IFAT, another highly sensitive sero-
ogical method that may present highly variable results, with
ates ranging from 34 to 82.9% (Table 1).14,20 Additionally, the
FAT has other disadvantages such as not being suitable for
utomation, high cross-reactivity in patients with Chagas dis-
ase, paracoccidioidomycosis, pemphigus foliaceus, and some
eep mycoses.21 All those diseases are considered endemic
Table 3 – Results of Leishmania mexicana exo-Ag ELISA among 3
one rheumatic marker.
Rheumatic marker ELISA with Leishmania mexicana exo-antigens re
ASO Positive 
Negative 
CRP Positive 
Negative 
RF Positive 
Negative 
Total 
ASO, anti-streptolysin O; CRP, C-reactive protein; RF, rheumatoid factor.in some parts of South America, especially in Midwestern
Brazil.3,22
The exo-Ag ELISA showed similar results when compared
to the index of positive tests obtained by other authors
with different antigens. The exo-Ag ELISA sensitivity val-
ues were close to those of tests that satisfactorily used
chromatography-puriﬁed antigenic fractions.23,24 As an anti-
gen, the intact parasite contains membrane glycoproteins that
act as powerful epitopes due to constant exposure to the host
immunological system. Despite comprising glycoproteins that
are not present on the parasite membrane, the exo-Ag ELISA
sensitivity was similar to that of immunoenzymatic assays
that used intact promastigotes.25
The exo-Ag ELISA speciﬁcity was not perfect in a control
group of apparently healthy patients with no epidemiological
history of ATL (Table 2). Although they do not fulﬁl the com-
posite reference standard for the deﬁnition of ATL, it is not
possible to completely rule out subclinical Leishmania infec-
tions once the disease is presenting a growing incidence in
otherwise free areas, such as periurban regions. Other subclin-
3 rheumatic disease patients, testing positive for at least
sults (n) Speciﬁcity (95% CI)
3
9
6
7 60.61
4 (43.68–75.32)
4
33
i s . 2 0
r
1
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ical diseases that could produce nonspeciﬁc antibody binding
should also be considered.7,26
The speciﬁcity was moderate when Chagas patients’ sera
were tested (Table 2). Studies have shown that the speci-
ﬁcity values for Chagas disease range from a total lack of
speciﬁcity27 or low values such as 5.5%28 to values as high as
83.33%.24 The latter study used puriﬁed glycoprotein antigens
that were less likely to cause nonspeciﬁc reactions. However,
the challenge of cross-reactivity with other trypanosomatids
remains and is likely due to the presence of antigenic deter-
minants with similar structures.8,29 Therefore, it is necessary
to purify the exo-Ag ELISA antigens in order to improve the
test speciﬁcity against other parasitic diseases such as Chagas
disease.
When the serum samples of patients with rheumatic
diseases were studied, substantial numbers of nonspeciﬁc
reactions were observed in all sera in which rheumatic
markers were present (Table 3). We highlight the C-reactive
protein that presented a considerable number of false positive
results. This protein is present in patients with inﬂamma-
tory conditions as a result of classical pathway activation,
which relies on the presence of immunoglobulins. These
immunoglobulins seem to exhibit nonspeciﬁc behaviours in
these patients, which would explain the high exo-Ag ELISA
cross-reactivity.
In samples from patients with deep mycoses, two reac-
tions with absorbances above the cut-off value were observed
in sera from patients with sporotrichosis. ATL can be mis-
taken for sporotrichosis either by clinical manifestations or
by immunological test cross-reactions, and therefore the dif-
ferential diagnosis between these two infections is relevant.30
It is also important to remember the possibility of co-
infection by Sporothrix schenkii and Leishmania, as described
previously.31
It should be pointed out that the use of L. mexicana anti-
gens, a species not endemic in Midwestern Brazil, can result
in higher frequency of false positive and false negative results.
However, as previously stated, the relative difﬁculty in man-
aging Leishmania (Viannia) braziliensis can be an obstacle for
species-speciﬁc antigens production. By observing the occur-
rence of nonspeciﬁc reactions, we can note the need to study
immunoenzymatic reactions with L. mexicana exo-antigen
antigenic fractions. Additionally, we might suggest the sep-
aration of the proteins that comprise L. mexicana exo-antigens
for using in immunoblot tests with sera from patients with
other diseases, in order to identify the less reactive bands that
provide higher speciﬁcities.
Based on the indicators of validity, we  conclude that the
results obtained in this study allow for the recommendation of
the exo-AG ELISA for ATL diagnosis once it presented a reason-
able accuracy compared to classical methods. Cost evaluations
are necessary to completely deﬁne the role of this technique
on large scale.
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